Rain Enhancement Technologies Holdco, Inc. (RAIN) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the RAIN Oncology Fourth Quarter and Full Year 2022 Earnings Score. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of LifeSci Advisors. Thank you. You may begin. Thank you, operator, and good afternoon, everyone. With me today on the phone are Avinash Phalanke, Chief Executive Officer of RAINN Oncology, Robert Doble, Chief Scientific Officer, Richard Brice, Chief Medical Officer, and Nelson Kabatuan, SVP of Finance. During today's call, Avinash will provide an update on the broader strategic vision for the Mila Demetan franchise. Bob will review the biology and rationale of P53 reactivation as it relates to our Mila Demetan clinical program. Richard will provide an update on RAIN's clinical strategy. And Nelson will review the financials. Before we begin, I'd like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon RAINN's current expectations and involves assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties as described in RAINN's annual report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission and other SEC filings. All forward-looking state...